- News Home
17 April 2014 12:48 pm ,
Vol. 344 ,
Officials last week revealed that the U.S. contribution to ITER could cost $3.9 billion by 2034—roughly four times the...
An experimental hepatitis B drug that looked safe in animal trials tragically killed five of 15 patients in 1993. Now,...
Using the two high-quality genomes that exist for Neandertals and Denisovans, researchers find clues to gene activity...
A new report from the Intergovernmental Panel on Climate Change (IPCC) concludes that humanity has done little to slow...
Astronomers have discovered an Earth-sized planet in the habitable zone of a red dwarf—a star cooler than the sun—500...
Three years ago, Jennifer Francis of Rutgers University proposed that a warming Arctic was altering the behavior of the...
- 17 April 2014 12:48 pm , Vol. 344 , #6181
- About Us
Moratorium Urged on Germ Line Gene Therapy
19 September 2000 7:00 pm
A report issued 18 September by the American Association for the Advancement of Science (AAAS, publisher of Science) has called for a total moratorium on attempts to cure genetic diseases by altering the genome in ways that would be passed from one generation to the next. Human germ line gene therapy--and possibly some techniques in use today--would be unsafe and unethical, the report concludes. And it urges the government to create an independent panel to monitor public and private research and prevent such risky experiments.
In preparing the report, ethicists Mark Frankel and Audrey Chapman of the AAAS staff in Washington, D.C., consulted for 2 years with a score of advisers in gene therapy, ethics, sociology, and theology. They found wide support for a moratorium on germ line gene therapy. But they went further, proposing a moratorium on therapies that might change human DNA accidentally, including methods used by some reproductive medicine clinics.
The DNA editing methods that make it possible to revise mammalian genomes are "developing impressively," said Theodore Friedmann, director of the gene therapy program at the University of California, San Diego, and adviser to the AAAS authors. It would be exciting to try to "fix" genetic diseases by editing the human genome, Friedmann said, but he is convinced that the risks of injury--not just to the individuals immediately affected but to future generations--outweigh the potential benefits.
The AAAS report reflects this concern, although it supports expanded basic research in this field as well as clinical gene therapy for cells other than sperm and eggs. The report proposes that a national group of experts and lay people be established to keep tabs on the field, particularly on private firms that might try to sell genetic "enhancement" therapies offering to improve the beauty, brains, or brawn of children.
At present, no public or private labs are proposing to do germ line gene therapy. But the report questions therapies used by reproductive medicine clinics, including one in which cytoplasm from a donor egg--complete with mitochondria--is injected into an egg slated for fertilization. A child born from this process may inherit mitochondrial DNA from both eggs. The AAAS report classifies this as a type of "inheritable genetic modification" and argues that it should not be done at present.
Jacques Cohen of St. Barnabas Medical Center in Livingston, New Jersey, which developed the technique, agrees that it is "highly experimental." But he argues that it is "an incredible stretch" to classify it as germ line gene therapy. He says he has found no harmful effects from the technique, which has enabled infertile women to give birth to healthy babies--15 at last count.